Plasmatech Biopharmaceuticals Inc. (PTBI) 3.78 $PTBI
PlasmaTech Biopharmaceuticals Announces Closing of Upsized $7 Million Private Placement
Marketwired - Fri Apr 24, 8:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had closed an upsized $7 million private placement of common stock with Knoll Capital Management and one additional global institutional fund manager. The private financing is comprised of 2,333,333 shares of common stock at a price of $3.00 per share. PlasmaTech plans to use the proceeds of the financing to accelerate development of its proprietary Salt Diafiltration (SDF(TM)) Plasma Protein technology, working capital and general corporate purposes.
PTBI: 3.78 (+0.15)
Ongoing Trial May Lead to Better Understanding of Oral Mucositis, a Debilitating Side Effect Affecting Many Cancer Patients
Marketwired - Thu Apr 23, 10:40AM CDT
An ongoing clinical trial at UCLA's Jonsson Comprehensive Cancer Center evaluating the use of an oral wound rinse for the management of oral mucositis/stomatitis, may pave the way for better understanding and prevention of the debilitating side effect seen in many patients undergoing chemotherapy and radiotherapy.
PTBI: 3.78 (+0.15), NVS: 104.28 (-1.22)
New Breakthroughs to Avoid Shortage of Treatment for Those With Inherited COPD
Marketwired - Wed Apr 15, 8:03AM CDT
Chronic Obstructive Pulmonary Disease (COPD) is a term used to describe progressive lung diseases including emphysema, chronic bronchitis and refractory (non-reversible) asthma. This disease is characterized by shortness of breath, coughing, wheezing, chest tightness and other symptoms.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals Bolsters Scientific Advisory Board With Alpha-1 Expert Charlie Strange, M.D.
Marketwired - Tue Apr 14, 8:04AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had appointed Charlie Strange, M.D. to its Scientific Advisory Board (SAB). Dr. Strange is a highly regarded thought leader in the Alpha-1 community, and has extensive clinical experience in designing and managing Alpha-1 clinical studies. The Company believes his advice and counsel will help accelerate development and approval of its proprietary SDF Alpha(TM) biologic drug.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. To Its Scientific Advisory Board
PR Newswire - Tue Apr 07, 8:05AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, appointed Robert Sandhaus, MD, Ph.D. to its Scientific Advisory Board (SAB). The appointed SAB will serve as a strategic resource to the company as it continues to develop and commercialize its proprietary plasma fractionation platform, Salt Diafiltration Process (SDF(TM)), and its lead biologic candidate, SDF Alpha, its proprietary alpha-1 protease inhibitor (A1PI).
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals' Announces $5 million private placement
PR Newswire - Thu Apr 02, 8:05AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, today announced that it has entered into a definitive purchase agreement with Knoll Capital Management, a leading healthcare institutional investor, to raise $5.0 million in a private placement of common stock. The private financing is comprised of 1,666,667 shares of common stock, at a price of $3.00 per share. PlasmaTech plans to use the proceeds of the financing to accelerate development of its proprietary Salt Diafiltration (SDF(TM)) Plasma Protein technology, working capital and general corporate purposes.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements
PR Newswire - Wed Apr 01, 7:15AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, today provided an overview of the Company's 2014 achievements and a strategic update for 2015. The highlighted achievements below demonstrate the progress the Company has made in the areas of business development with multiple corporate partnerships for its MuGard programs, the FDA clearance of the ProctiGard product, and the in-licensing of the SDF Plasma technology platform, culminating in the successful recapitalization, financing and up listing to NASDAQ in the fourth quarter of last year. Additionally, today the Company announces that it has filed its Annual Report on Form 10-K for the year ended December 31, 2014, with the Securities and Exchange Commission.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea
PR Newswire - Tue Mar 31, 7:45AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi"
(KSE: 128940) has received marketing approval in Korea from the country's Ministry of Food and Drug Safety ("MFDS" and the Korea Testing & Research Institute (KTR) for MuGard, its oncology supportive-care treatment for the management of oral mucositis. Under the terms of the previously announced marketing agreement, Hanmi will import MuGard from the United States and marketing will commence. Hanmi intends to market MuGard in Korea under the trade name Mucogard.
PTBI: 3.78 (+0.15)
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 13.42 (-0.25), RNN: 0.73 (-0.01), PTBI: 3.78 (+0.15), DARA: 0.81 (+0.04), BIND: 6.84 (-0.33)
PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference - NEW TIME SLOT
PR Newswire - Tue Mar 10, 8:10AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has a new presentation slot at the 27th Annual ROTH Capital Partners Conference which is being held on March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
PTBI: 3.78 (+0.15)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 3.12 (unch), GLMD: 9.14 (-0.72), PTBI: 3.78 (+0.15), CNAT: 6.66 (-0.15), GALT: 3.29 (-0.04), SRNE: 10.52 (-0.15), CELG: 118.71 (+2.62), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), CFRX: 5.37 (+0.09), ICPT: 283.20 (-2.22), JUNO: 56.66 (-1.06), CORT: 6.32 (-0.12)
PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference
PR Newswire - Tue Mar 03, 8:10AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has been invited to present at the 27th Annual ROTH Capital Partners Conference which is being held on March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals To Present at 17th Annual BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 10:13AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that Scott Schorer, CEO, will be presenting a corporate update at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 9, 2015, at 5:00 pm ET in the Park South room at the Waldorf Astoria Hotel in New York, NY. Management from PTBI is available throughout the conference for one-on-one meetings as well.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Wed Jan 14, 8:00AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting at Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA this week. Details are as follows:
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals Announces Closing of Upsized $7 Million Private Placement
Marketwired - Fri Apr 24, 8:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had closed an upsized $7 million private placement of common stock with Knoll Capital Management and one additional global institutional fund manager. The private financing is comprised of 2,333,333 shares of common stock at a price of $3.00 per share. PlasmaTech plans to use the proceeds of the financing to accelerate development of its proprietary Salt Diafiltration (SDF(TM)) Plasma Protein technology, working capital and general corporate purposes.
PTBI: 3.78 (+0.15)
Ongoing Trial May Lead to Better Understanding of Oral Mucositis, a Debilitating Side Effect Affecting Many Cancer Patients
Marketwired - Thu Apr 23, 10:40AM CDT
An ongoing clinical trial at UCLA's Jonsson Comprehensive Cancer Center evaluating the use of an oral wound rinse for the management of oral mucositis/stomatitis, may pave the way for better understanding and prevention of the debilitating side effect seen in many patients undergoing chemotherapy and radiotherapy.
PTBI: 3.78 (+0.15), NVS: 104.28 (-1.22)
New Breakthroughs to Avoid Shortage of Treatment for Those With Inherited COPD
Marketwired - Wed Apr 15, 8:03AM CDT
Chronic Obstructive Pulmonary Disease (COPD) is a term used to describe progressive lung diseases including emphysema, chronic bronchitis and refractory (non-reversible) asthma. This disease is characterized by shortness of breath, coughing, wheezing, chest tightness and other symptoms.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals Bolsters Scientific Advisory Board With Alpha-1 Expert Charlie Strange, M.D.
Marketwired - Tue Apr 14, 8:04AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had appointed Charlie Strange, M.D. to its Scientific Advisory Board (SAB). Dr. Strange is a highly regarded thought leader in the Alpha-1 community, and has extensive clinical experience in designing and managing Alpha-1 clinical studies. The Company believes his advice and counsel will help accelerate development and approval of its proprietary SDF Alpha(TM) biologic drug.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. To Its Scientific Advisory Board
PR Newswire - Tue Apr 07, 8:05AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, appointed Robert Sandhaus, MD, Ph.D. to its Scientific Advisory Board (SAB). The appointed SAB will serve as a strategic resource to the company as it continues to develop and commercialize its proprietary plasma fractionation platform, Salt Diafiltration Process (SDF(TM)), and its lead biologic candidate, SDF Alpha, its proprietary alpha-1 protease inhibitor (A1PI).
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals' Announces $5 million private placement
PR Newswire - Thu Apr 02, 8:05AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, today announced that it has entered into a definitive purchase agreement with Knoll Capital Management, a leading healthcare institutional investor, to raise $5.0 million in a private placement of common stock. The private financing is comprised of 1,666,667 shares of common stock, at a price of $3.00 per share. PlasmaTech plans to use the proceeds of the financing to accelerate development of its proprietary Salt Diafiltration (SDF(TM)) Plasma Protein technology, working capital and general corporate purposes.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements
PR Newswire - Wed Apr 01, 7:15AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, today provided an overview of the Company's 2014 achievements and a strategic update for 2015. The highlighted achievements below demonstrate the progress the Company has made in the areas of business development with multiple corporate partnerships for its MuGard programs, the FDA clearance of the ProctiGard product, and the in-licensing of the SDF Plasma technology platform, culminating in the successful recapitalization, financing and up listing to NASDAQ in the fourth quarter of last year. Additionally, today the Company announces that it has filed its Annual Report on Form 10-K for the year ended December 31, 2014, with the Securities and Exchange Commission.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea
PR Newswire - Tue Mar 31, 7:45AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi"
(KSE: 128940) has received marketing approval in Korea from the country's Ministry of Food and Drug Safety ("MFDS" and the Korea Testing & Research Institute (KTR) for MuGard, its oncology supportive-care treatment for the management of oral mucositis. Under the terms of the previously announced marketing agreement, Hanmi will import MuGard from the United States and marketing will commence. Hanmi intends to market MuGard in Korea under the trade name Mucogard. PTBI: 3.78 (+0.15)
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 13.42 (-0.25), RNN: 0.73 (-0.01), PTBI: 3.78 (+0.15), DARA: 0.81 (+0.04), BIND: 6.84 (-0.33)
PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference - NEW TIME SLOT
PR Newswire - Tue Mar 10, 8:10AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has a new presentation slot at the 27th Annual ROTH Capital Partners Conference which is being held on March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
PTBI: 3.78 (+0.15)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 3.12 (unch), GLMD: 9.14 (-0.72), PTBI: 3.78 (+0.15), CNAT: 6.66 (-0.15), GALT: 3.29 (-0.04), SRNE: 10.52 (-0.15), CELG: 118.71 (+2.62), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), CFRX: 5.37 (+0.09), ICPT: 283.20 (-2.22), JUNO: 56.66 (-1.06), CORT: 6.32 (-0.12)
PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference
PR Newswire - Tue Mar 03, 8:10AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has been invited to present at the 27th Annual ROTH Capital Partners Conference which is being held on March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals To Present at 17th Annual BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 10:13AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that Scott Schorer, CEO, will be presenting a corporate update at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 9, 2015, at 5:00 pm ET in the Park South room at the Waldorf Astoria Hotel in New York, NY. Management from PTBI is available throughout the conference for one-on-one meetings as well.
PTBI: 3.78 (+0.15)
PlasmaTech Biopharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Wed Jan 14, 8:00AM CST
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting at Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA this week. Details are as follows:
PTBI: 3.78 (+0.15)
